Traders should monitor the March 30 earnings call for full-year 2025 financials and any updates on commercial traction or clinical progress. The $900K in 9-month revenue suggests modest commercial activity; meaningful upside would require accelerated adoption or positive trial updates.
Price Chart
Executive Summary
RenovoRx announced it will host a conference call on March 30, 2026, to discuss its Q4 and full-year 2025 financial results and business updates. The company disclosed that it generated approximately $900,000 in RenovoCath sales during the first nine months of 2025 and is advancing its Phase III TIGeR-PaC trial in pancreatic cancer, with enrollment expected to complete in early 2026.
Key Financial Metrics
Key Facts
- RenovoRx will host a conference call on March 30, 2026, to discuss Q4 and full-year 2025 financial results.
- Approximately $900,000 in revenue was generated from RenovoCath sales during the first nine months of 2025.
- Phase III TIGeR-PaC trial in locally advanced pancreatic cancer remains on track to complete enrollment in H1 2026, with final data expected in 2027.
- The company is pursuing cost-neutral registry and investigator-initiated trials to expand the use of its TAMP platform.
- RenovoCath has received first commercial purchase orders, with repeat orders from existing customers and expansion into NCI-designated cancer centers.
Financial Impact
Approximately $900,000 in revenue for first nine months of 2025; no full-year or Q4 financials provided.
Risk Factors
- Revenue remains limited and concentrated in early commercialization phase.
- Phase III trial results are not expected until 2027, creating long-term execution and clinical risk.
- Forward-looking statements dominate the release; actual financials and operational progress remain pending.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers